News | January 26, 2024
Laurus Labs inks JV agreement with KRKA, Slovenia
The registered capital of the newly founded company is € 50 million
The registered capital of the newly founded company is € 50 million
The orphan drug designation by the EC is issued for drugs which are intended to treat diseases that affect fewer than five in 10,000 people in the European Union
Produodopa is the first-and-only subcutaneous 24-hour infusion of levodopa-based therapy for the treatment of severe motor fluctuations
Sonoma will manufacture Ocudox by Avenova with packaging similar to NovaBay’s Avenova products
TALZENNA is the first and only PARP inhibitor approved in combination with standard of care XTANDI for mCRPC patients in the European Union
Liraglutide belongs to the class of glucagon like peptide 1 receptor agonist (GLP?1 RA) drugs
The CVMP recommends the product for approval for the treatment and persistent killing of fleas
Dr. Reddy's will make a US$ 7.5 million upfront payment to Coya
Decision on EU marketing authorisation expected for momelotinib by early 2024
Yesafili, received marketing authorization approval from the European Commission for the European Union
Subscribe To Our Newsletter & Stay Updated
